Novo is asking Lilly to not only withdraw the ads, but run a corrective ad campaign, in addition to seeking compensation for financial damages
However, studies in humans do not show consistent results of GLP-1RAs on energy expenditure, as some studies do not demonstrate changes [111, 112], while other studies show increased [113115] or decreased energy expenditure post-GLP-1RA therapy [80, 116]
Do not discontinue Rybelsus without medical advice, as this may adversely affect glycaemic control
If the product you're evaluating makes claims that sound like medical treatment, assume it's either FDA-approved (which glutathione isn't for most indications) or operating outside regulatory boundaries
pinnata could be administered at higher, selectively cytotoxic doses without significant harm to normal cells
This erosion pattern is why generic manufacturers compete intensely for first-filer status: being first in a market with one competitor is fundamentally different from being fifth in a market with ten